BIOMIT Center for Molecular Immunology - CIM

Terms and Conditions


These terms and conditions regulate the access and use of WebCim and all its subdomains or secondary domains including its contents and services, made available through the Internet Portal WebCim may update at any time the conditions set forth in this document, as well as legal notices, guidelines and / or use regulations and, as the case may be, substitute, complete and / or modify the Terms and Conditions set out herein. It is recommended that you periodically consult the Terms and Conditions. By accessing WebCim you will be accepting the current terms and conditions.


You agree to use WebCim solely for legitimate purposes and in a way that does not infringe, restrict or inhibit the use and enjoyment of WebCim services, or to not use this page to perform activities contrary to law, morals, good Customs or established public order. You agree not to access, or attempt to access, any of the services using automated means, including scripts or web crawlers. Likewise, it undertakes not to engage in any activity that interferes or interrupts the services or the servers and networks connected to them.


The publishers will make all the efforts that are reasonable to try to guarantee the availability and accessibility of the page, as well as to its services, twenty-four hours a day during all the days of the year. However, sometimes, and, for example, due to causes such as the provision of new connections, address changes and / or the updating of maintenance operations that, in general, imply the suspension of access or use of the page , interruptions may occur for as long as it is necessary to undertake these tasks.

Contents and services

Here are some of the contents and services offered by WebCim:


News related to the Center of Molecular Immunology and the production process of medicines.


News of scientific, commercial and business events.

Distribution lists

Send to the users expressly subscribed by email the monthly summary of the articles published in WebCim. WebCim will not disclose your email to third parties and will only use this information for the purposes stated above.

Modification of contents and services

WebCim reserves the right to modify, at any time and without prior notice, the presentation and configuration of its contents and services. You expressly acknowledge and agree that at any time you can interrupt, deactivate and / or cancel any of the contents and / or services.

Copyright of the information

The copyright on the information of third parties that is published in WebCim belongs to their respective authors and their publication in WebCim is done without profit and with an informative purpose.

Links to content published by Cubadebate

WebCim authorizes third parties to include in their websites access to the information published by WebCim using links to do so.

Links to third-party websites

WebCim may contain links to websites that are controlled and maintained by third parties. WebCim makes every effort to make the published links available but is not responsible for the content or the availability of that information.


WebCim reserves the right to enable the comment mechanism for some of the articles or content published. The comments are the opinion of the user, it is not necessarily the position or opinion of WebCim. When they are inserted, they enter the queue of moderation and must be published in a short period of time. In any case, WebCim reserves the right to publish them, eliminating those that are off topic or use rude, violent, racist, offensive or contrary to the law.

Notifications to WebCim

In the cases that you detect irregularities, violations of these terms and conditions or want to clarify any doubt regarding our services you can write us to the email account Editors of WebCim, January 17, 2019

Phone Board:
General Direction:
15 Street and 216 Street, Siboney, Playa, La Habana, Cuba. A.P 16040, La Habana 11600, Cuba
Postal Code:
11 600
Post Office Box:
16 040



Frequent Questions

How can I access the therapeutic vaccines against lung cancer?

Cuba has 2 therapeutic vaccines for advanced lung cancer: CIMAvax EGF ® and VAXIRA® (Racotumomab). Both therapeutic vaccines have a health record in the indication of advanced non-small cell lung cancer (NSCLC) stage III and IV, after the first line of chemotherapy. The main clinical benefit of these vaccines has been demonstrated in an increase in survival and improvement in quality of life, as well as a broad safety profile. How to get vaccines? Foreigners should contact the Cuban Medical Services who will evaluate each case as part of a comprehensive patient care program, with commercial value. -Cuban Medical Services. Web page: .; E-mail: Telephone: (537) 209-0977 Fax: (537) 203-1590. You can also make your request for care stating the reason for your request, a medical summary and personal data directly to: International Clinic of the Hermanos Ameijeiras Hospital. Calle San Lázaro # 701 esq. a Belascoaín, Centro Habana, La Habana, C.P: 10400, Cuba. Telephone: (537) 8761029, (537) 8761030, (537) 8761683. Email: International Health Center - La Pradera Calle 15 e / 222 A y 234, Reparto Siboney, Playa Municipality, Havana, Cuba Telephone: (+537) 273 7467 Ext. 403 (+537) 2737202. Email:   If you want a treatment outside of Cuba. You can contact the following companies with commercial rights in the region for CIMAvax EGF® DELTA Laboratories S.A. Colombia. General Manager: Mr. Alejandro Castaño. Address: Cra. 46 # 19 Sur 117 Medellín, Colombia, South America. Tel. + 57-4-334 40 33. Cell: +57 - 311-301 8257 E-mail: Skype: Alejandrodelta. URL:   Libra Laboratorios, Paraguay S.A Commercial Manager: Mr. Pablo Moreira. Address: Pedro Ciancio 1443 between Santiago and San Cosme B Jara Asunción Tel. (595-21) 228 370. Cell: (595) 986 679300 E-mail:

Mas preguntas frecuentes...


Welcome to the CIM survey, we value your opinion and thank you for dedicating your time

We would love to know how you like our site
50% (22897 votes)
Very Good
32% (14763 votes)
5% (2686 votes)
11% (5099 votes)
0% (280 votes)